Daily Pill Optimizes Insulin Use and Reduces A1c For Type 1 Diabetes
Dec 15, 2020
Editor: David L. Joffe, BSPharm, CDE, FACA
Author: A'Kira Shavers, PharmD Candidate, South College School of Pharmacy
An oral medication that does not increase risk of low blood sugar could provide an alternative to insulin.
New studies have investigated a once-daily pill to optimize insulin therapy and reduce HbA1c among adults diagnosed with type 1 diabetes. Recent research from a phase 2 Simplici-T1 trial showed a new pill known as a novel liver-selective glucokinase activator, also known as TTP399, showed a placebo-subtracted HbA1c reduction of 0.32% at 12 weeks when compared with a placebo. Carmen Valcarce, Ph.D., chief scientific officer of vTv Therapeutics, told Healio that this might be the first adjunctive therapy that showed improved glycemic control without the increased risk of hypoglycemia. She also suggested that the fear of hypoglycemia is what keeps many patients from achieving their target goals. TTP399 works by selectively activating glucokinase, a key regulator of glucose metabolism in the liver. When this activation happens, an increase in glucose utilization is present, which lowers blood glucose. Simplici-T1 is the first study to test the actual activation of glucokinase in people with type 1 diabetes, while evaluating the once-daily oral TTP399’s effects compared to insulin therapy....
Agreement to pay later is required for access to the full text of this article. You will be charged only after your use reaches $5.00 (US) of site content. The costs of producing a newsletter like Diabetes in Control have been increasing, which is why we are asking our readers to help support our ability to continue to bring you quality information about diabetes through charging a minimal price to read certain articles. Thank you for helping to support Diabetes in Control.